Association of MAGE A1-6 Expression with Lung Cancer Progression

Abstract

The melanoma-associated antigen (MAGE) genes are known to be expressed in various kinds of tumors including lung cancer. Although they are studied as targets for immunotherapy and tools for early detection of lung cancer, the correlation between MAGE expression and the prognosis in lung cancer has not been clarified. In this study, we evaluated the relationship between MAGE A1-6 gene expression and the clinical prognosis in lung cancer.Bone marrow aspirations were performed in 60 patients who were diagnosed as lung cancer and underwent lung cancer surgery between 2007 and 2008. Each bone marrow was examined using nested reverse transcription- polymerase chain reaction (RT-PCR) with the MAGE common primer to detect MAGE A1-6. Overall survival rate, disease-free survival rate, recurrence, and distant metastasis were reviewed retrospectively. Survival periods were analyzed using SPSS ver. 20.0.Of the total 60 lung cancer patients, 9 patients (15%) had MAGE A1-6. MAGE A1-6-positive patients showed poor overall survival and overall disease-free survival rates (43.8 ± 26.1, 43.2 ± 26.9 months, respectively) compared with MAGE A1-6-negative patients (54.4 ± 17.2, 44.8 ± 22.1 months, respectively). No significant difference was shown in either survival rates.In conclusion, MAGE A1-6 expression of bone marrow in lung cancer patients correlated with poor survival rates. We suggest that MAGE A1-6 may be considered as a novel prognostic factor for lung cancer which leads to effective follow-up and treatment.

MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells

“…The survival analysis revealed that a high level of MAGE-A1 expression was correlated with unfavorable outcomes of LUAD. All the above data concurred with the studies that showed high expression levels and a prognostic role of MAGE-A1 in LUAD [43, 45, 46].…”

“…As a member of the MAGE-A antigens, which are the best characterized CTAs, MAGE-A1 is also strictly tumor-specific and is detected in various solid tumors [40–42]. Although MAGE-A1 expression in LC has also been reported [43–45], the detailed and exclusive function of MAGE-A1 in LUAD remains unclear. After MAGE-A1 was screened as the most promising candidate by the aforementioned bioinformatics analyses, a set of investigations was performed to thoroughly examine the characteristics of MAGE-A1 in LUAD.…”

Co-stimulatory and co-inhibitory Immune Markers in Solid Tumors With MET Alterations

“…MAGEA1, a classic CT antigen, is a tumor-specific member of the MAGEA antigen family whose expression has been previously reported in several solid tumors [ 43 , 44 ]. Its expression has also been associated with progression and survival in NSCLC, but the specific mechanism for this phenomenon remains unknown [ 45 , 46 ]. CT antigens are ideal targets for cancer immunotherapy, and MAGEA1 has been shown to be actionable in vitro and in vivo by chimeric antigen receptor (CAR) T-cell therapy in lung adenocarcinoma cells, where the lung adenocarcinoma cells were effectively destroyed by IFN-γ secretion due to MAGEA1 inhibition [ 47 ].…”

A new tool for early diagnosis of rheumatoid arthritis using a combined biomarkers; synovial MAGE-1 mRNA and serum anti-CCP and R

“…Furthermore, the adopted methods for the amplification of MAGE-1 and β actin genes were entirely different between both studies. On the other hand, it was reported that there is a correlation between MAGE-A gene expression and the poor prognosis of epithelial ovarian and lung cancers suggesting not only its diagnostic role but also its role as a prognostic biomarker for the treatment and effective follow up [ 30 , 31 ]. Moreover, MAGE-A1 gene is playing an important role in the inflammation process, which could be attributed to T cells activation via immune response system activation [ 32 ], consequently enhancing cytokines up-regulation and providing widespread activation of the immune response [ 20 ].…”